fda approved semaglutide Novo Nordisk's weight-loss pill wins approval A big win for Wegovy:

At baseline, the mean age was 46 years, 81% were female, 76% were White, 19% were Black or African American and 2% were Asian

However, we do know a few things based on emerging studies and general knowledge about weight loss and low-fat dieting (which is generally recommended while taking GLP-1s)

The STEP trial program, which included over 15,000 participants, demonstrated that semaglutide produces average weight loss of 15-17% of body weight when combined with lifestyle modifications

Tirzepatide was found to significantly reduce oral contraceptive pharmacokinetics by approximately 60%

The amount of weight lost may vary depending on various factors, but many clients experience a loss of about 5% of their initial body weight